TRACON Pharmaceuticals Announces Publication Of Phase 2 Clinical Data For TRC102 In Patients With Glioblastoma In Clinical Cancer Research; Study Highlights Activity Of TRC102 Combined With Temodar Chemotherapy In Recurrent Glioblastoma

6/11/24 8:04:41 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $TCON alert in real time by email

Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiotherapy

Consistent with the TRC102 Mechanism of Action, Extended Survival was Demonstrated in Patients with Activation of DNA Damage Response Pathways Prior to TRC102 Treatment

Get the next $TCON alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TCON

Date	Price Target	Rating	Analyst
2/23/2022	$10.00	Outperform	Baird

More analyst ratings

$TCON
Press Releases

Fastest customizable press release news feed in the world

TRACON Pharmaceuticals Announces it Will Wind Down Operations
SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB:TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors. The board of directors appointed Craig R. Jalbert, age 62, as the Company's CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in
7/30/24 4:44:46 PM ET
$TCON
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did not meet the primary endpoint of 11% Company will focus on exploring strategic alternatives, that may include a variety of strategic transactions such as a reverse merger, acquisition, sale of all assets, or other strategic transactions leveraging its in-house Product Development Platform of CRO-independent clinical trial execution SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON) today announced the objective response rate (ORR) by blinded independent central review (BICR) in the fully
7/1/24 9:00:00 AM ET
$TCON
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiotherapy Consistent with the TRC102 Mechanism of Action, Extended Survival was Demonstrated in Patients with Activation of DNA Damage Response Pathways Prior to TRC102 Treatment SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science c
6/11/24 8:00:00 AM ET
$TCON
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$TCON
Financials

Live finance-specific insights

TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2024. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. "With ENVASARC fully enrolled we are focused on leveraging our Product Development Platform to generate non-dilutive capital through either an additional license or by replacing a CRO and executi
5/14/24 4:01:00 PM ET
$TCON
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Tuesday, May 14, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results. Date:May 14, 2024Time:4:30 pm Eastern Time (1:30 pm Pacific Time)Conference Call:In order t
5/7/24 4:01:00 PM ET
$TCON
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. "We are on track to complete enrollment of 80 patients treated with single agent envafolimab in the ongoing pivotal ENVASARC trial later this quarter. We expect to report updated
3/5/24 4:02:00 PM ET
$TCON
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$TCON
Market Insights

Live Market Insights

HC Wainwright & Co. Downgrades TRACON Pharma to Neutral
HC Wainwright & Co. analyst Edward White downgrades TRACON Pharma (OTC:TCON) from Buy to Neutral.
7/1/24 1:43:47 PM ET
$TCON
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 77.4% to $6.19 during Monday's pre-market session. The company's market cap stands at $3.5 million. ENDRA Life Sciences (NASDAQ:NDRA) shares moved upwards by 35.9% to $0.14. The company's market cap stands at $2.4 million. Venus Concept (NASDAQ:VERO) stock increased by 22.86% to $1.15. The company's market cap stands at $7.3 million. Tharimmune (NASDAQ:THAR) shares moved upwards by 19.4% to $4.0. The company's market cap stands at $3.1 million. TRACON Pharma (NASDAQ:TCON) stock moved upwards by 19.04% to $1.5. The market value of their outstanding shares is at $4.0 million. Kineta (NASDAQ:KA) shares moved upwards by
6/17/24 8:07:49 AM ET
$APVO
$BIMI
$BJDX
$ELUT
Biotechnology: Pharmaceutical Preparations
Health Care
Other Pharmaceuticals
Medical/Dental Instruments
Why Broadcom Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Shares of Broadcom Inc. (NASDAQ:AVGO) rose sharply in today's pre-market trading after the company posted stronger-than-expected results for its second quarter. The company declared a quarterly dividend of $5.25 per share and also announced a 10-for-1 forward stock split. Broadcom boosted its fiscal year 2024 revenue guidance to approximately $51 billion, up from approximately $50 billion. Broadcom shares surged 13.5% to $1,698.20 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Neo-Concept International Group Holdings Limited (NASDAQ:NCI) rose 79.3% to $1.17 in pre-market trading. Fangdd Network Group Ltd. (NASDAQ:DUO) sh
6/13/24 8:16:57 AM ET
$AEMD
$AIU
$AVGO
$CARA
Medical/Dental Instruments
Health Care
Other Consumer Services
Real Estate

$TCON
Leadership Updates

Live Leadership Updates

TRACON Pharmaceuticals Announces it Will Wind Down Operations
SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB:TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors. The board of directors appointed Craig R. Jalbert, age 62, as the Company's CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in
7/30/24 4:44:46 PM ET
$TCON
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
TRACON Pharmaceuticals Announces Appointment of Carol Lam to its Board of Directors
SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Carol Lam to its Board of Directors. "We are very pleased to welcome Carol to our Board of Directors," said Dr. Charles Theuer, President and Chief Executive Officer of TRACON. "She brings a global perspective on technology development acquired through her extensive experience as deputy General Counsel
10/13/21 8:00:00 AM ET
$TCON
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award
SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and the granting of an inducement equity award to Dr. Marczi. "We are very pleased to welcome Brenda to the senior management team at TRACON," said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. "
7/20/21 8:05:00 AM ET
$TCON
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

TRACON Pharmaceuticals Announces Publication Of Phase 2 Clinical Data For TRC102 In Patients With Glioblastoma In Clinical Cancer Research; Study Highlights Activity Of TRC102 Combined With Temodar Chemotherapy In Recurrent Glioblastoma

Chat with this insight

Recent Analyst Ratings for $TCON

$TCON Press Releases

Fastest customizable press release news feed in the world

TRACON Pharmaceuticals Announces it Will Wind Down Operations

TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform

TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients

$TCON SEC Filings

SEC Form 15-12G filed by TRACON Pharmaceuticals Inc.

SEC Form EFFECT filed by TRACON Pharmaceuticals Inc.

SEC Form EFFECT filed by TRACON Pharmaceuticals Inc.

$TCON Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$TCON Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form 3 filed by new insider Lazar David E.

Brown Scott B. was granted 3,500 shares, increasing direct ownership by 16% to 25,128 units (SEC Form 4)

Theuer Charles was granted 7,000 shares, increasing direct ownership by 2% to 406,417 units (SEC Form 4)

Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc. (Amendment)

$TCON Financials

Live finance-specific insights

TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

$TCON Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Baird initiated coverage on TRACON Pharmaceuticals with a new price target

Alliance Global Partners initiated coverage on TRACON Pharmaceuticals with a new price target

Tracon Pharmaceuticals upgraded by BTIG Research with a new price target

$TCON Market Insights

Live Market Insights

HC Wainwright & Co. Downgrades TRACON Pharma to Neutral

12 Health Care Stocks Moving In Monday's Pre-Market Session

Why Broadcom Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket

$TCON Leadership Updates

Live Leadership Updates

TRACON Pharmaceuticals Announces it Will Wind Down Operations

TRACON Pharmaceuticals Announces Appointment of Carol Lam to its Board of Directors

TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award

Recent Analyst Ratings for
$TCON

$TCON
Press Releases

$TCON
SEC Filings

$TCON
Insider Trading

$TCON
Large Ownership Changes

$TCON
Financials

$TCON
Analyst Ratings

$TCON
Market Insights

$TCON
Leadership Updates